These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 19459997)

  • 1. Baseline incontinence severity is predictive of the percentage of patients continent after receiving once-daily trospium chloride extended release.
    Staskin DR; Cardozo L
    Int J Clin Pract; 2009 Jun; 63(6):973-6. PubMed ID: 19459997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Once-daily administration of trospium chloride extended release provides 24-hr coverage of nocturnal and diurnal symptoms of overactive bladder: an integrated analysis of two phase III trials.
    Ginsberg DA; Oefelein MG; Ellsworth PI
    Neurourol Urodyn; 2011 Apr; 30(4):563-7. PubMed ID: 21268101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trospium chloride once-daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome: an integrated analysis of two randomised, phase III trials.
    Staskin DR; Rosenberg MT; Sand PK; Zinner NR; Dmochowski RR
    Int J Clin Pract; 2009 Dec; 63(12):1715-23. PubMed ID: 19930332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Once-daily trospium chloride 60 mg extended-release provides effective, long-term relief of overactive bladder syndrome symptoms.
    Zinner NR; Dmochowski RR; Staskin DR; Siami PF; Sand PK; Oefelein MG
    Neurourol Urodyn; 2011 Sep; 30(7):1214-9. PubMed ID: 21462240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of once-daily trospium chloride extended-release in male patients with overactive bladder.
    MacDiarmid SA; Ellsworth PI; Ginsberg DA; Oefelein MG; Sussman DO
    Urology; 2011 Jan; 77(1):24-9. PubMed ID: 20970833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Obesity is associated with a more severe overactive bladder disease state that is effectively treated with once-daily administration of trospium chloride extended release.
    Chancellor MB; Oefelein MG; Vasavada S
    Neurourol Urodyn; 2010 Apr; 29(4):551-4. PubMed ID: 19634167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial.
    Staskin D; Sand P; Zinner N; Dmochowski R;
    J Urol; 2007 Sep; 178(3 Pt 1):978-83; discussion 983-4. PubMed ID: 17632131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study.
    Dmochowski RR; Sand PK; Zinner NR; Staskin DR
    Urology; 2008 Mar; 71(3):449-54. PubMed ID: 18342185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Once-daily trospium chloride 60 mg extended release in subjects with overactive bladder syndrome who use multiple concomitant medications: Post hoc analysis of pooled data from two randomized, placebo-controlled trials.
    Sand PK; Rovner ES; Watanabe JH; Oefelein MG
    Drugs Aging; 2011 Feb; 28(2):151-60. PubMed ID: 21275440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trospium chloride once-daily extended release is efficacious and tolerated in elderly subjects (aged ≥ 75 years) with overactive bladder syndrome.
    Sand PK; Johnson Ii TM; Rovner ES; Ellsworth PI; Oefelein MG; Staskin DR
    BJU Int; 2011 Feb; 107(4):612-20. PubMed ID: 20707790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended-release trospium chloride improves quality of life in overactive bladder.
    Dmochowski RR; Rosenberg MT; Zinner NR; Staskin DR; Sand PK
    Value Health; 2010; 13(2):251-7. PubMed ID: 19818062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time to onset of improvement in symptoms of overactive bladder using antimuscarinic treatment.
    Rudy D; Cline K; Harris R; Goldberg K; Dmochowski R
    BJU Int; 2006 Mar; 97(3):540-6. PubMed ID: 16469022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial.
    Chapple C; Schneider T; Haab F; Sun F; Whelan L; Scholfield D; Dragon E; Mangan E
    BJU Int; 2014 Sep; 114(3):418-26. PubMed ID: 24552358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The overactive bladder-symptom composite score: a composite symptom score of toilet voids, urgency severity and urge urinary incontinence in patients with overactive bladder.
    Zinner N; Harnett M; Sabounjian L; Sandage B; Dmochowski R; Staskin D
    J Urol; 2005 May; 173(5):1639-43. PubMed ID: 15821526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolterodine extended release is efficacious in continent and incontinent subjects with overactive bladder.
    Rovner ES; Rackley R; Nitti VW; Wang JT; Guan Z;
    Urology; 2008 Sep; 72(3):488-93. PubMed ID: 18639327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
    Herschorn S; Swift S; Guan Z; Carlsson M; Morrow JD; Brodsky M; Gong J
    BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trospium chloride and oxybutynin hydrochloride in a german study of adults with urinary urge incontinence: results of a 12-week, multicenter, randomized, double-blind, parallel-group, flexible-dose noninferiority trial.
    Zellner M; Madersbacher H; Palmtag H; Stöhrer M; Bödeker RH;
    Clin Ther; 2009 Nov; 31(11):2519-39. PubMed ID: 20109997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Achieving continence with antimuscarinic therapy for overactive bladder: effects of baseline incontinence severity and bladder diary duration.
    Wein AJ; Khullar V; Wang JT; Guan Z
    BJU Int; 2007 Feb; 99(2):360-3. PubMed ID: 17155987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicenter phase III trial studying trospium chloride in patients with overactive bladder.
    Rudy D; Cline K; Harris R; Goldberg K; Dmochowski R
    Urology; 2006 Feb; 67(2):275-80. PubMed ID: 16461077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trospium chloride extended release is effective and well tolerated in women with overactive bladder syndrome.
    Sand PK; Dmochowski RR; Zinner NR; Staskin DR; Appell RA
    Int Urogynecol J Pelvic Floor Dysfunct; 2009 Dec; 20(12):1431-8. PubMed ID: 19727537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.